Study evaluates F-18 FDG-PET/CT in diagnosing giant cell arteritis | Pain untreated around the world, report finds | Morphine, ibuprofen tied to inadequate pediatric pain relief
October 17, 2017
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP ⋅   FORWARD
Top Story
Study evaluates F-18 FDG-PET/CT in diagnosing giant cell arteritis
Patients with newly diagnosed giant cell arteritis who received high-dose glucocorticoid prednisone had significantly increased mean total F-18 FDG-PET/CT vascular uptake scores and mean FDG uptake in six of eight vascular territories, compared with healthy controls, Canadian researchers reported in The Journal of Rheumatology. The findings also showed that a total PET/CT score of 9 or higher was ideal in distinguishing those with GCA from controls, while systemic symptoms, reduced hemoglobin levels and elevated platelet counts were tied to increased total PET/CT scores among those with GCA.
Rheumatology Advisor (10/16) 
LinkedIn Twitter Facebook Google+ Email
Learn In Demand Skills in Health Care
GW's clinical research, health care quality and regulatory affairs programs prepare you to become a leader, able to meet the evolving nature of health care.
Learn More
ADVERTISEMENT
Clinical News & Research
Pain untreated around the world, report finds
A report from The Lancet Commission on Global Access to Palliative Care and Pain Relief estimates that 26 million people with serious illnesses -- including more than 2.5 million children -- in 172 countries receive no pain relief or palliative care. "The pain gap is a massive global health emergency which has been ignored, except in rich countries," said commission leader Felicia Knaul of the University of Miami Miller School of Medicine.
HealthDay News (10/13) 
LinkedIn Twitter Facebook Google+ Email
Morphine, ibuprofen tied to inadequate pediatric pain relief
A study in Pediatrics found that only 29.9% of children with musculoskeletal injuries who received oral morphine and ibuprofen in the emergency department had a pain score under 30 mm on the visual analog scale, indicating mild pain, as did just 33% of those receiving only ibuprofen and 29.3% of those receiving only oral morphine. The findings also showed more adverse events among those who took both drugs and those who took morphine alone, compared with those in the ibuprofen group, but no serious adverse events were reported.
Medscape (free registration) (10/12) 
LinkedIn Twitter Facebook Google+ Email
Traumatic experiences tied to heart disease risk among women
Women who experienced at least three traumatic events, such as sexual harassment, natural disasters or the death of a child, were more likely to have poorer endothelial function compared with women who had fewer traumatic experiences, according to a study presented at the annual meeting of the North American Menopause Society. The findings were based on data for 272 postmenopausal and perimenopausal women.
Medical News Today (10/11) 
LinkedIn Twitter Facebook Google+ Email
Industry Report
NIH, 11 drugmakers collaborate on cancer therapy research
NIH, 11 drugmakers collaborate on cancer therapy research
(NIH)
The National Institutes of Health will collaborate with 11 drug companies in a $215 million public-private partnership to advance studies on immunotherapy research. The five-year Partnership for Accelerating Cancer Therapies will be devoted to identifying, developing and validating chemical signatures in the body to help determine which patients would benefit from cancer treatments.
Reuters (10/12),  STAT (tiered subscription model) (10/12) 
LinkedIn Twitter Facebook Google+ Email
 
Pfizer's neuropathic pain drug approved by FDA
The FDA approved Pfizer's Lyrica CR, or pregabalin, extended-release tablets CV as a once-a-day treatment for patients with neuropathic pain related to diabetic peripheral neuropathy and postherpetic neuralgia. A clinical trial demonstrated at least 50% improvement in pain intensity in 73.6% of patients who used Lyrica CR compared with 54.6% who received placebo.
Seeking Alpha (free registration) (10/12) 
LinkedIn Twitter Facebook Google+ Email
News from the Field
Survey: 48% of primary care physicians happy with practice income
A Medscape survey of more than 1,150 physicians in 25 specialties found 48% of primary care physicians were somewhat or very satisfied with their practice income, compared with 55% of doctors in other specialties. Overall, physicians said their reputation for providing quality care and referrals from family and friends were the top reasons new patients sought care from them.
Medscape (free registration) (10/11) 
LinkedIn Twitter Facebook Google+ Email
Health Policy
States' lawsuit seeks to prevent administration from scrapping CSRs
Attorneys general in 18 states and Washington, D.C., filed a lawsuit against the Trump administration Friday seeking to stop the government from ending cost-sharing reduction payments under the Affordable Care Act. New York Attorney General Eric Schneiderman said President Donald Trump's decision to scrap the payments "with no warning or even a plan to contain the fallout is breathtakingly reckless," but Senate Minority Leader Chuck Schumer, D-N.Y., says he's optimistic that Democrats and Republicans will be able to reach a deal during federal spending negotiations in December, if not before.
Reuters (10/13) 
LinkedIn Twitter Facebook Google+ Email
Advancing Health Care
AHIMA examines patients' access to EHRs via patient portals
AHIMA surveyed 167 consumers and found that 82% used their providers' patient portals to access their EHRs in 2016, up from less than 5% in 2013, and 90% of those users expressed satisfaction with their experience. Findings also showed that 35% of users employed portals for viewing laboratory results, 22% for making appointments and 19% each for requesting medication renewals and sending secure messages.
Healthcare Informatics online (10/11),  Health IT Security (10/11) 
LinkedIn Twitter Facebook Google+ Email
From SNMMI
Submit your abstract for the AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy
This groundbreaking collaboration between the American Association for Cancer Research (AACR) and SNMMI, taking place Feb. 14-17 in San Diego, will bring together imaging scientists with physicians and cancer biologists in basic, translational and clinical research to discuss, promote and support the application and use of molecular imaging in cancer biology and therapy. Learn more and submit your abstract today. Submission deadline is Oct. 31.
LinkedIn Twitter Facebook Google+ Email
Don't lose your SNMMI member benefits­
If you forgot to renew your SNMMI membership for 2017-2018, renew online today to reinstate your access to exclusive member benefits. Keep your subscription to The Journal of Nuclear Medicine (JNM), free CE credit opportunities through the SNMMI Learning Center and discounts on all SNMMI programs, products and services. SNMMI membership is valued at more than $1,000. Pay a fraction of that price to continue to receive these member benefits and more. Regain access to SNMMI member benefits -- renew online today.
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
Editor's Note
Correction
There was an error in Monday's SNMMI SmartBrief regarding the summary about FDG-PET/MR in pediatric epilepsy. The summary should have stated that FDG-PET/MR was compared with PET/CT. SmartBrief regrets the error.
LinkedIn Twitter Facebook Google+ Email
  
  
The test of a vocation is the love of the drudgery it involves.
Logan Pearsall Smith,
writer
  
  
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information